Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Demographics and clinical characteristics were similar between treatment groups except for a slight trend toward decreased tibialis anterior muscle strength in the treatment group ( Table 1 ).

also in 4,078 other papers